Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) will present at the Virtual Investor 2023 Companies to Watch Event on January 17, 2023, at 10:00 AM ET. CEO Jeffrey Eisenberg will showcase the company's advancements in immune-oncology technologies aimed at treating hard-to-treat cancers. A live video webcast will be available on the company's Investors website page, with a replay accessible for 90 days post-event. Xenetic specializes in DNase platforms for cancer treatment and the XCART™ technology for personalized CAR T therapies.

Live video webcast on Tuesday, January 17^th at 10:00 AM ET

FRAMINGHAM, MA / ACCESSWIRE / January 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 10:00 AM ET.

A live video webcast of the presentation will be available on the Events page in the Investors section of the Company's website (www.XeneticBio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

The Company is also developing its personalized CAR T platform technology, XCART™, to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-Cell lymphomas.

For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.

Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/734057/Xenetic-Biosciences-Inc-to-Present-at-the-Virtual-Investor-2023-Companies-to-Watch-Event

FAQ

When will Xenetic Biosciences present at the Virtual Investor 2023 event?

Xenetic Biosciences will present on January 17, 2023, at 10:00 AM ET.

Who is presenting for Xenetic Biosciences at the event?

CEO Jeffrey Eisenberg will present on behalf of Xenetic Biosciences.

How can I watch the Xenetic Biosciences presentation?

You can watch the presentation via a live video webcast on the company's Investors page.

What are the focus areas of Xenetic Biosciences?

Xenetic Biosciences focuses on immune-oncology technologies and developing treatments for hard to treat cancers.

What technologies is Xenetic exploring for cancer treatment?

Xenetic is advancing its DNase platform and the personalized CAR T platform technology, XCART™.